Just as advancing technology has furthered our understanding of how the nervous system recovers, technology also enables the development of novel approaches to treatment. Because nervous system disease and injury often lead to severely impaired function, patients and families are willing to try anything, so therapies are often adopted with little evidence that they actually work. Evidence shows that comprehensive rehabilitation programs produce better outcomes, but it is still not understood what components of these multifaceted programs are critical to their success. Functional neuroimaging and other modalities now allow monitoring of neurophysiologic changes that can be paired with assessments detailing clinical changes, furthering our understanding of the factors that influence the recovery process. This article discusses several novel and emerging therapies in neurorehabilitation as well as recent multistudy reviews of selected treatments. Vasodilator 1 Other 2 GABA = +-aminobutyric acid; AMPA = !-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid. Adapted from Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008;55(3):363Y389.
THERAPIES IN THE EARLY POSTINJURY PERIOD Hypothermia
Evidence from animal models supports the neuroprotective effects of hypothermia in global cerebral ischemia (postYcardiac arrest), traumatic brain injury (TBI), spinal cord injury (SCI), and stroke. 1 Hypothermia has become the standard of care postYcardiac arrest. 2 Although clinical evidence suggests a benefit in TBI, 3 evidence is conflicting for both SCI and stroke. Povlischock and Wei suggest that evidence points to slow rewarming combined with immunophilin ligands such as cyclosporine A as a key to improved results. The Brain Trauma Foundation and the American Association of Neurological Surgeons guidelines task force issued a Level III recommendation for optional use of hypothermia for adults with TBI. 4 Recent evidence suggests that the combination of neuroprotective medications with hypothermia may be beneficial and deserves additional study. 5 Zhao and colleagues 6 provide a review of the benefits and limitations of hypothermic intervention, highlighting the effects on biochemical and pathologic processes.
Pharmacologic Interventions TBI, SCI, and stroke are all associated with a period of secondary injury that evolves over hours to days resulting from a cascade of biochemical and physiologic events. Several biochemical derangements are responsible for secondary injury and include changes in calcium homeostasis, increased free radical production, lipid peroxidation, mitochondrial dysfunction, inflammation, and apoptosis. This time period provides a window of opportunity for therapeutic intervention, with the potential to reduce secondary damage and thus improve long-term clinical outcomes.
Many preclinical studies in both TBI and stroke suggest that compounds that target mechanisms involved in secondary injury both salvage brain tissue and improve function. Yet all of the approaches that have been tested in phase III clinical trials have failed to clearly demonstrate efficacy. 7, 8 Table 7 -1 shows a synopsis of clinical neuroprotective trials in stroke. Some therapies, such as the use of corticosteroids post-TBI, should be abandoned, as a recent multitrial review demonstrated increased mortality and disability in patients with TBI receiving corticosteroids. 9 Evidence points to the pathophysiologic heterogeneity of TBI and stroke, inadequate information to determine optimal dosing and timing, as well as suboptimal clinical and statistical design. 10, 11 Numerous trials remain ongoing and involve known compounds such as progesterone, erythropoietin, statins, and phosphodiesterase inhibitors. Other early strategies, such as decompressive craniectomy, show promise in selected patients. Approaches combining several therapies and improved research design may be critical to success. 5, 7, 12 
THERAPIES IN THE POSTACUTE PERIOD Pharmacologic Therapies
Drugs enhancing neurotrophins. Brain-derived neurotrophic factor (BDNF), among other neurotrophins, has emerged as a major modulator of both synaptic transmission and plasticity in many regions of the CNS. BDNF has been shown to increase the survival of neurons, to increase synaptic transmission, 13 and to enhance long-term potentiation along with short-term synaptic plasticity. 14 Secondary brain injury after ischemic and traumatic insults results from a combination of cytotoxic, inflammatory, ischemic, and apoptotic processes. Several lines of evidence indicate that BDNF may play a role in limiting the secondary injury that occurs after TBI and stroke by altering gene expression in injured cells. 16 Administration of BDNF after TBI, stroke, and SCI in animals has been shown to be neuroprotective and promote plasticity and recovery. 17, 18 Selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, and monoamine oxidase inhibitors all increase BDNF levels in the frontal cortex. 19 Statins upregulate BDNF, increase neurogenesis, and are associated with improvement after TBI and ischemia. 7, 20 Compounds that alter histones, thereby altering gene expression through chromatin remodeling, increase BDNF expression and promote neurogenesis. 21 Although no clinical recommendations can yet be given, additional animal studies and early clinical investigations are underway.
Amphetamine. Over the past 50 years, numerous animal studies have shown that amphetamine combined with task-relevant training improves outcomes following TBI and ischemia. 22 A small double-blind, placebo-controlled clinical trial provided evidence that damphetamine combined with physical therapy improved short-term motor function after stroke. 23 Another placebocontrolled study in patients with subacute stroke evaluated d-amphetamine administration combined with 1 hour of speech therapy 3 times per week for a total of 10 sessions. Patients receiving d-amphetamine improved significantly, and at 6 months they still demonstrated a persistent positive trend despite no additional drug or therapy. 24 Results of clinical trials since have been variable. This variability can possibly be attributed to study design issues such as stroke size and location; dosing and timing of drug; and timing, type, and intensity of physical therapy. Despite concerns about the potential negative cardiovascular effects of amphetamine, studies to date have not shown a difference in adverse events between drug and placebo in subjects given amphetamine within 1 week following stroke. 22 The NIH-sponsored Amphetamine-Enhanced Stroke Recovery (AESR) study is evaluating the impact of the timing and duration of therapy.
Dopaminergic drugs. Several studies have looked at the effects of other dopaminergic agents, such as levodopa, bromocriptine, amantadine, and methylphenidate, on promoting recovery and improving alertness, attention, memory, and initiation. These studies were generally small, producing variable results. The most convincing evidence supports the use of amantadine at doses of 200 mg to 400 mg per day to improve arousal and executive functioning in patients with TBI. 25, 26 In one study showing improvements in executive functioning after administration of amantadine, PET revealed an increase in glucose metabolism in the left prefrontal cortex. 27 The magnitude of the increase in glucose metabolism correlated with the degree of improvement in executive function.
Studies evaluating methylphenidate after brain injury and stroke have shown mostly positive results. Methylphenidate appears to have its greatest effect on improving speed of mental processing, tests of attention, and motor performance. 28, 29 Administration of methylphenidate to patients with moderate to severe TBI while they are still in the intensive care unit may reduce length of stay. 30 In 2006, the Neurobehavioral Guidelines Working Group recommended the use of methylphenidate in patients with TBI with impairments in attentional skills and processing speed. 31 
KEY POINTS
h Brain-derived neurotrophic factor modulates synaptic transmission and plasticity in the CNS.
h Amphetamine may improve recovery after stroke when combined with a therapy program.
h Dopaminergic drugs improve arousal and attention after traumatic brain injury.
Adverse reactions to these dopaminergic medications are rare at the doses used in clinical practice but may include paranoia, anxiety, agitation, increases in heart rate and blood pressure, and lowering of the seizure threshold.
Piracetam. After reviewing several studies involving more than 220 stroke patients with aphasia, a Cochrane Review concluded that piracetam may be effective as an adjunct to therapy in the treatment of aphasia after stroke. 32 Piracetam's mechanism of action is not clear. It is not available in the United States at the time of this writing.
Acetylcholinesterase inhibitors. Because TBI commonly affects the basal frontal lobes, cholinergic deficit is common. Patients with TBI also frequently have impairments in memory. In clinical trials, the effects of donepezil and rivastigmine are consistently positive, improving memory, attention, and speed of processing. 28, 33 The Neurobehavioral Guidelines Working Group and a recent comprehensive review 33 both recommend the use of donepezil and rivastigmine in patients with moderate to severe TBI during the subacute and chronic periods of recovery. Side effects include nausea, diarrhea, vomiting, muscle cramping, and fatigue, but these can often be minimized by slowly escalating the dose. Anticholinesterase inhibitors should not be used in patients with symptomatic bradycardia or atrioventricular block. There are no reports that anticholinesterase inhibitors lower the seizure threshold.
Selective serotonin reuptake inhibitors. Ample evidence exists that depression adversely affects functional recovery following stroke and TBI and that treating depression improves recovery. 34 Only limited evidence exists that SSRIs may improve functioning following stroke or TBI independent of their effects on depression. 28 Modafinil. Modafinil is approved to improve wakefulness in adults with narcolepsy, obstructive sleep apnea, and shift work disorder. It is frequently used in clinical settings to improve arousal and attention following TBI and stroke with few reported significant side effects and the clinical impression that it is beneficial in selected patients. The mechanism of action is unclear. Currently, few studies exist to either refute or support its use. 33 Polypharmacy. In clinical practice, various combinations of pharmacologic agents are frequently used in patients with TBI and stroke. This is particularly true for those patients with severe deficits, especially impairments of arousal, attention, initiation, and impulsivity. In some situations, patients may be on more than three psychoactive agents, at times including both dopaminergic and antidopaminergic drugs. Each practitioner or institution appears to have a unique approach. Pharmacologic treatment will be reviewed from a clinical perspective in the article ''Traumatic Brain Injury.''
Medications with Adverse Effects on Recovery
Agitation, anxiety, insomnia, and sleepwake cycle disturbance are all common following TBI and stroke, resulting in disruption of the rehabilitation program as well as inappropriate behavior. Strong evidence from both animal and human studies demonstrates that typical +-aminobutyric acid agonists (benzodiazepines) produce residual cognitive and behavioral effects that outlast their duration in the bloodstream. 35, 36 There have also been longstanding concerns that the use of antipsychotics after TBI and stroke may reinstate deficits that had abated as well as delay recovery. 37, 38 Although immediate control of dangerous behaviors is KEY POINTS h Acetylcholinesterase inhibitors improve memory after traumatic brain injury.
h Benzodiazepines and antipsychotics appear to slow recovery from traumatic brain injury and stroke.
sometimes urgently needed (see the article ''Traumatic Brain Injury''), other environmental and pharmacologic interventions should be considered for management of agitation, impulsivity, and sleep disruption. 39 
Nonpharmacologic Therapies
Constraint-induced movement therapy. Constraint-induced movement therapy (CIMT) involves restraining the unaffected extremity during therapy sessions with the affected extremity and for several hours or constantly at other times for periods of several weeks to over a month (Case 7-1). In addition to involving repetitive massed practice (which mounting evidence shows is critical to motor skill recovery), CIMT reduces sensory input to the uninvolved extremity. CIMT has been shown to produce clinical improvement and changes in fMRI in both acute and chronic patients poststroke. 40, 41 In a recent review, Wittenberg and Schaechter 42 noted that both fMRI and transcranial magnetic stimulation (TMS) demon-strated changes in brain activation that correlated with CIMT. The changes were variable and likely correlated with the extent of stroke-induced damage to the descending corticospinal tract.
A recent review 43 of CIMT for the upper extremity poststroke concluded that disability is moderately improved immediately following the intervention. Although additional information is needed to assess long-term benefit, a recent reexamination of the data from the Extremity Constraint Induced Therapy Evaluation (EXCITE) trial noted that subjects needed to perform above a functional threshold in order to maintain gains or continue to improve after the CIMT ceased. 44 Another recent study 45 compared CIMT to bilateral arm training in patients with stroke and found better functional use of the affected extremity after CIMT for patients with mild to moderate stroke. Proximal arm motor impairment improved more after bilateral training. CIMT has also been used with success in patients with cerebral palsy 46 and TBI. 47
KEY POINT
h Constraint-induced movement therapy improves upper extremity function in conjunction with cortical reorganization.
Case 7-1
An 18-month-old girl with cerebral palsy and a left hemiparesis presented to the clinic. She ambulated with an ankle-foot orthosis and had reasonable gross motor function in every muscle group in her left upper extremity. She tended not to use the arm in any activity. Her parents were very motivated and supportive.
She was referred to occupational therapy for constraint-induced movement therapy and underwent periodic casting of her unimproved right upper extremity for 3 weeks at a time with 3 weeks off. During this time she also received intensive therapy, partly with a therapist and also through a home program. The initial attempts were difficult, with much crying and difficulties with cooperation, but her parents and occupational therapist persisted over a 2-year period.
At the end of 2 years, she was using her left upper extremity spontaneously in general activities and had individual finger control.
Comment. This case illustrates the potential impact of constraint-induced movement therapy on upper extremity function given a long span of time and a consistent approach.
Clinical implementation of CIMT is limited for several reasons. To participate, patients need active wrist and hand movement, including at least 10 degrees of wrist and finger extension, which limits its application to patients with mild to moderate motor impairment. Additionally, patients with TBI with cognitive-behavioral impairments and children may not be receptive to wearing a cast or other restraint on the uninvolved extremity, which may reduce cooperation with therapies or cause anxiety in caregivers and parents. Finally, CIMT repetitive practice sessions are time intensive (which can increase costs), can be frustrating, and require a high degree of motivation.
Transcranial magnetic stimulation and transcranial direct current stimulation. The theory behind CIMT is that in addition to forced use of the involved extremity, thus increasing input to the involved hemisphere, input from the uninvolved extremity to the uninvolved hemisphere is reduced. 48 fMRI studies show increased activation of motor areas in both hemispheres when the affected extremity is moved soon after stroke. 49,50 Concentration of activity within the motor areas correlates with good recovery, while persistence of activation in the contralesional hemisphere correlates with less recovery. 49, 51 In addition, the lateralization of neural activity during unimanual activity is, in part, related to interhemispheric inhibition between motor areas exerted via transcallosal connections that are disrupted following stroke. 52 In theory, persisting activation of the unaffected hemisphere may limit activation of the involved hemisphere, thus limiting postinjury recovery. Even in healthy subjects, inhibition of the ipsilateral motor cortex or facilitation of the contralateral motor cortex by TMS improves upper extremity motor speed and motor task acquisition. 53, 54 After extensive review of studies employing either TMS or transcranial direct current stimulation (tDCS) in patients with stroke, Nowak and colleagues 55 concluded that evidence strongly suggests that TMS and tDCS are both beneficial and safe in promoting motor recovery following stroke. Improvement was noted following inhibition of the uninvolved hemisphere as well as stimulation of the involved hemisphere. The beneficial effects of TMS and tDCS on cortical excitability outlast the stimulus for minutes to hours and thus may be paired with poststimulation therapy. Repeated activation over several days or weeks and in combination with training appears to enhance both the effect size and duration of improvement.
Currently, TMS and tDCS are not part of the therapeutic regimen following stroke or TBI, as many questions still exist regarding these therapies, such as the optimal frequency and intensity of the stimulation, the appropriate timing and duration of the program postinjury, and the appropriate patient selection in terms of severity and location of injury. Although studies are underway, the effects of pairing either TMS or tDCS with standard rehabilitation approaches, CIMT, or robot-assisted therapy are largely unknown.
Robot-assisted therapy. After stroke and TBI, many patients have little or no ability to use their upper extremity. Robotic devices are able to deliver highintensity, reproducible therapy and may be useful in those with little voluntary movement as well as those with greater ability. A review 56 existed in the type, timing, frequency, and duration of training.
In a multicenter randomized controlled trial involving 127 patients more than 6 months poststroke who had moderate to severe upper extremity impairment, Lo and colleagues 57 compared intensive robot-assisted therapy to intensive conventional therapy and to limited therapy. No difference existed at 12 weeks immediately following the intervention. At 36 weeks, both the robot-assisted group and those receiving intensive conventional therapy showed significant improvements in motor function compared to those receiving more limited therapy. In another multicenter study, this one involving 109 patients 3 to 9 months poststroke, Kutner and colleagues 58 compared therapist-supervised repetitive task practice to robot-assisted therapy. Both produced significant and equivalent improvements in upper extremity function. The investigators concluded that robotics may reduce therapist labor, reduce costs, and foster acceptance of approaches that involve repetitive practice, such as CIMT.
Body weightYsupported treadmill training. Body weightYsupported treadmill training (BWSTT) involves compensating for a percentage of the subject's body weight, usually via suspension with a harness over a treadmill. The subject then walks on the treadmill at varying speeds and with varying percentages of body-weight support. In addition, one or more therapists may assist by advancing a paretic leg or providing tactile or verbal cues. Working on a treadmill facilitates an even gait speed and provides more gait cycles and repetition than could occur over ground, while reducing the need for trunk control by displacing weight through the harness suspension. As noted above, research has shown that repetition is critical to skill acquisition. See Video Segments 19 through 22 for an example of BWSTT in a patient with intracerebral hemorrhage.
Patients with hemiparesis, ataxia, partial spinal cord injury, and cerebral palsy may all benefit from this approach (Case 7-2). Preliminary research has demonstrated improvements in measured gait parameters after BWSTT in stroke, 59Y61 spinal cord injury, 62Y64 multiple sclerosis, 65 and pediatric patients. 66, 67 Yen and colleagues 61 were also able to demonstrate changes in cortical excitability that correlated with functional improvement following BWSTT but not after general physical therapy.
The practical efficacy of BWSTT has been limited by the physical and time demands placed on therapists who must manually facilitate stepping during the early phases of therapy in some patients. It was hypothesized that a robotic device that facilitates stepping might enhance the adoption of BWSTT. Unfortunately, Hornby and colleagues 60 demonstrated that therapist-assisted BWSTT was superior to robotic-assisted BWSTT in a group of patients with chronic stroke. A recent Cochrane Review 68 of studies on overground gait training was unable to determine whether overground physical therapy gait training improves gait function in patients with chronic stroke but concluded that it did produce an improvement in walking speed. In addition to potentially enhancing functional and neurologic recovery of gait, BWSTT may also serve to provide general aerobic exercise in patients with neurologic impairments at a level that they would not be able to achieve through other means.
Exercise. General aerobic exercise improves cardiorespiratory function and plays a role in reducing risk for vascular diseases, including stroke. New evidence is emerging that aerobic exercise may also enhance neural plasticity, cognitive h Body weightYsupported treadmill training promotes gait improvement following traumatic brain injury, stroke, and partial spinal cord injury. function, and motor recovery. Physical activity increases neurogenesis in the hippocampus, directly affects synaptic plasticity, and increases angiogenesis, 69, 70 at least in part through increasing levels of BDNF.
Saunders and colleagues 71 reviewed 24 trials involving 1147 patients with stroke that included cardiorespiratory, strength, and mixed exercise programs. Training improved fitness but not necessarily functional activities. The only consistent effect observed was that cardiorespiratory training involving walking improved a wide range of walking parameters and reduced dependence on others during walking. After reviewing 14 trials with 659 patients, French and colleagues 72 found that repetitive, task-specific training resulted in meaningful functional gains when compared with usual care. No significant adverse effects were noted. Evidence was insufficient to demonstrate maintenance of gains at 6 to 12 months after the training ended. The role of exercise does not seem surprising. Healthy subjects need to continue to exercise to maintain fitness levels, so one could assume that the same is likely true for persons with neurologic injuryVpotentially even more so. Experienced clinicians know the deleterious effects of even a relatively short period of immobility during an illness or after an injury in patients with neurologic impairment.
Physical exercise in humans appears to protect against the development of KEY POINT h General exercise programs promote fitness and appear to enhance CNS plasticity.
Case 7-2
A 45-year-old woman had an ''over the handlebars'' bicycle accident during a race while going downhill at about 45 miles per hour. She sustained a C4-C5 fracture dislocation and had only minimal motor function with considerable preserved sensation. Acutely she required a tracheostomy and ventilation but was weaned from the ventilator at 2 months. At that time she had 3/5 strength in her legs, 4/5 proximal arm strength, and 2/5 hand strength. Proprioception was seriously impaired in both lower extremities.
After inpatient rehabilitation she required minimal assistance with activities of daily living and was ambulating short distances with a walker and minimal assistance, albeit with a very irregular gait.
She began a body weightYsupported treadmill training (BWSTT) program for 1 hour a day 5 days a week. After 2 months her gait had noticeably improved, and she was ambulating in the community with a cane.
Beginning 9 months postinjury her walking began to decline because of increased pain and stiffness. MRI was negative for syrinx. She was started on baclofen and duloxetine. Therapy was intensified. After the addition of tizanadine and gabapentin, she resumed physical therapy in a therapy pool with a treadmill floor. She improved partially, but she never returned to the level she had achieved at 6 months postinjury.
She is awaiting an intrathecal baclofen trial and is hopeful that it will both improve her spasticity and provide additional pain control.
Comment. Reinnervation in partial spinal cord injury can lead to devastating neuropathic pain and spasticity. BWSTT is a useful therapy because it delivers repetitive, consistent walking. The intense repetition appears important to the process of recovery.
dementia. 73Y75 Devine and Zafonte 76 reviewed numerous animal and human studies and reached the following conclusions: (1) strong evidence from animal models of stroke and TBI demonstrates that physical exercise promotes neurocognitive recovery; (2) physical exercise programs appear to be safe in the subacute and chronic phase after stroke and TBI; and (3) preliminary evidence from widely varying human studies suggests a neurocognitive benefit, but more studies are needed.
Fitness exercise programs could be a simple, effective adjunct to promote brain plasticity following TBI and stroke. This intervention is noninvasive, generally safe, and also benefits general health and performance of daily activities. Functional neuroimaging may help shed light on the neurophysiology underlying the beneficial effects of exercise.
Peripheral stimulation techniques. Peripheral stimulation approaches include muscle vibration and peripheral nerve stimulation. For patients with severe paralysis, these techniques are an adjunct to facilitating movement. Sophisticated functional electrical stimulation devices provide a means for those with SCI to use their paralyzed extremities to walk and accomplish other tasks. 77 Advances in mechanical engineering, nanotechnology, and nervous system interfaces, in collaboration with knowledgeable clinicians, will hopefully further advance these devices.
In addition to facilitating muscle contraction, peripheral stimulation provides input to the paretic extremity, altering the excitability of the corticospinal pathway via modulation of motor cortex activity. 78, 79 Numerous recent reports show functional benefit when muscle vibration and peripheral nerve stimulation are applied to the affected extremities in conjunction with a therapy program. 80Y85 It remains unclear what frequency, intensity, duration, and timing postinjury produce the best results. Most reports show a drop-off in benefit after 2 to 6 months, but it is not known how many subjects were continuing to participate in activities using the affected extremities. Popović and colleagues 86 published a review of this topic.
Electrical stimulation of paralyzed muscles, particularly after SCI, reduces muscle atrophy and helps slow bone mineral density decline. 87 Cost of equipment, frequency of application, and practicality limit clinical and ongoing application.
Mental practice. Mental practice with motor imagery is commonly used in athletic skill training. Studies of patients with stroke suggest that mental practice may be useful as an adjunct to CIMT or other repetitive therapies in improving motor skills. 88, 89 Cortical reorganization was also noted. Evidence from TMS studies demonstrates that ''mirror neurons'' found in the premotor and parietal cortex are activated during motor imagery, action observation, and imitation. 90 Mental practice can be carried out independent of therapy sessions and may help to moderate physical demands and allow patients to rehearse a skill when therapy assistance is not available.
Constraint-induced language therapy. Based on the principles of other constraint-induced therapy programs, constraint-induced language therapy (CILT) uses a physical barrier between participants who are given tasks that require communication, thus forcing verbal communication. Members of the control group were allowed to use any means of communication during the task. Although the ability to communicate improved in both the control and CILT groups, the CILT subjects used more words, whereas the control subjects used more gestures. 91 Additionally, improvement correlated with KEY POINT h Functional electrical stimulation enhances somatosensory input to the brain. increased activation of the left hemisphere, previously noted to accompany better recovery from aphasia. 92 
CONCLUSION
The past decade has seen an incredible leap in our understanding of how the injured nervous system responds to drugs, central and peripheral stimulation, as well as other therapy approaches. In many situations, definitive conclusions remain elusive owing to heterogeneity in research design, subjects, and timing. Clinical implementation lags because of lack of time, limited funding and reimbursement, large required effort, and limited communication among the various disciplines involved in neurorehabilitation. Intensive rehabilitation is physically and mentally demanding for patients, many of whom have other active medical problems. It is tedious to work over and over again on tasks that one once took for granted.
The foundation supporting the concept that repetitive practice produces functional improvement and nervous system reorganization can be used in combination with emerging cellular and pharmacologic approaches. Coordination between research scientists and clinicians will improve study design as well as include more subjects.
More widespread clinical implementation of approaches known to produce superior outcomes needs to occur. The future holds great promise for restorative therapies. 
